[FVD] First Trust Value Line Dividend Indx Fnd

Overview

Type of security: Fund

Tags: Country, Dividend, Equity, ETF, Index Based, Large-cap, Not Inversed, Stocks, U.S., Unleveraged, Value

The data is delayed by 15 minutes.

 

Price: 28.19 Change: -0.01 (-0.04%)
Ext. hours: Change: 0 (0%)

chart FVD

Refresh chart

Strongest Trends Summary For FVD

FVD is in the long-term up 14% in 2 years and up 39% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the Value Line(R) Dividend Index(TM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is a modified equal-dollar weighted index comprised of U.S. exchange-listed securities of companies that pay above-average dividends and have potential for capital appreciation.

See how to gain 20% in 14 sec with TrendsInvesting

Technical Data
High 52 week34.39 Low 52 week28.86 Last close33.62 Last change-0.47%
RSI45.22 Average true range0.39 Beta0.79 Volume430.93 K
Simple moving average 20 days-0.89% Simple moving average 50 days-0.36% Simple moving average 200 days4.73%
Performance Data
Performance Week0% Performance Month-1.38% Performance Quart2.03% Performance Half5.08%
Performance Year12.14% Performance Year-to-date9.83% Volatility daily0.75% Volatility weekly1.67%
Volatility monthly3.42% Volatility yearly11.83% Relative Volume184.64% Average Volume837.86 K
New High New Low
Funds Characteristics
30-day SEC yield2.51 Average market capitalization Average weighted market capitalization Forward P/E
Gross expense ratio0.76% Index dividend yield Median market cap19.47 B Number of holdings173
Price to Book Value 2.37 Price to Earnings17.06 Total expense ratio Total net assets
Weighted market capitalization

Info

Characteristics:
NAME VALUE
Gross Expense Ratio0,76
30 Day Sec Yield2,51
Number Of Holdings173
Maximum Market Cap474.38 billion
Median Market Cap19.47 billion
Minimum Market Cap1.02 billion
P/E Ratio17,06
P/Bv Ratio2,37
P/Cf Ratio9,41
P/S Ratio1,45
Top Holdings:
NAME VALUE
Baxter International Inc.0,62
Teva Pharmaceutical Industries Ltd.0,61
British American Tobacco Plc0,6
Mccormick Company, Incorporated0,6
Merck Co., Inc.0,6
Unilever Plc0,6
Alliant Energy Corporation0,59
Anheuser-busch Inbev N.v.0,59
Canon Inc.0,59
Cisco Systems, Inc.0,59
Top Sectors:
NAME VALUE
Utilities26,04
Consumer Staples15,06
Financials12,06
Industrials10,44
Health Care9,38
Information Technology9,16
Consumer Discretionary8,04
Energy5,24
Telecommunication Services2,3
Materials2,28

News

2019-04-16 11:20:03 | A Bunch of Dividend ETFs Hitting All-Time Highs

2019-04-15 09:58:01 | Dividend ETF FVD Hits New 52-Week High

2019-03-20 16:50:00 | First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds

2018-12-24 14:10:07 | A Dividend ETF Investing Guide

2018-11-30 07:30:31 | Stanley Black & Decker: Institutional Holdings

2018-10-30 12:45:02 | Sanofi: Analysts’ Recommendations on October 30

2018-10-29 11:49:22 | GlaxoSmithKline’s Q3 2018 Earnings: Analysts’ Estimates

2018-10-23 07:32:11 | How Novartis’s Sandoz Performed in the Third Quarter

2018-10-19 10:05:02 | A Guide to Dividend ETF Investing

2018-10-18 13:53:16 | Novartis Missed Revenue Estimates in Q3 2018

2018-10-15 09:40:16 | Novartis in Q3 2018: Analysts Expect Revenue Growth

2018-10-11 07:30:40 | A Look at the Performance of Novartis’s Alcon

2018-10-10 10:30:53 | How Novartis’s Sandoz Business Has Been Performing Recently

2018-10-01 10:32:44 | How GlaxoSmithKline’s Pharmaceutical Business Performed

2018-08-14 07:31:28 | GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018

2018-07-24 12:05:00 | Chile’s Pension Risk Rating Commission Approves Sale of Additional First Trust ETF

2018-05-31 13:45:10 | Assessing GlaxoSmithKline’s Quarterly Revenues

2018-05-31 11:46:21 | How Novartis’s Valuation Compares

2018-05-17 09:53:45 | Novartis Gains Ground, Completes the AveXis Acquisition

2018-04-27 16:04:56 | GlaxoSmithKline’s 1Q18 Earnings: Revenue Trend

2018-04-25 13:00:02 | Sanofi’s 1Q18: Revenue Expected to Fall

2018-04-25 11:26:38 | Novartis Launches FocalView to Modernize Clinical Trials

2018-04-23 08:02:04 | What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings

2018-04-17 09:36:50 | Expectations from Novartis’s 1Q18 Earnings

2018-04-11 14:40:02 | Novartis’s Stock Performance following the AveXis Agreement

2018-03-29 08:10:33 | How Merck Stock Has Performed Recently

2018-03-13 17:40:02 | How Novartis’s Revenues Trended in 4Q17

2018-03-08 10:30:22 | Analyst Recommendations for Johnson & Johnson in February 2018

2018-03-02 08:43:19 | These Factors Could Drive SO’s Dividend Growth

2018-03-01 14:46:09 | Sanofi’s Quarterly Revenue Trend in 4Q17

2018-02-12 08:00:50 | First Trust Launches New Blockchain ETF To Meet Demand

2018-02-08 10:31:42 | A Look at Ablynx and Sanofi’s Existing Partnership

2018-02-02 14:00:49 | Novartis’s 4Q17 Revenues and Fiscal 2017 Revenues

2018-02-02 10:30:02 | GlaxoSmithKline Is Focused on Developing Oncology Asset GSK 916

2018-02-01 14:31:47 | Sanofi to Acquire Bioverativ

2018-01-30 16:26:49 | Trelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKline

2018-01-25 10:31:03 | How Is Novartis’s Tafinlar+Mekinist Positioned for 2018?

2018-01-12 10:33:07 | Why Assurant Has a Positive Outlook despite a Weak 2017

2017-11-15 09:01:58 | Behind Novartis’s Respiratory Drug Performance in 3Q17

2017-11-03 08:57:26 | An ETF For Dividend Achievers

2017-10-30 16:55:00 | Chile’s Pension Risk Rating Commission Approves Sale of Four Additional First Trust ETFs

2017-10-19 09:46:03 | How Do Aerospace and Defense Sector Dividends Look?

2017-09-20 17:29:00 | First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds

2017-09-20 07:38:08 | How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17

2017-09-18 14:19:40 | What Analysts Recommend for Novartis in September 2017

2017-09-11 12:32:16 | What Could Drive TechnipFMC’s Dividend Yield

2017-08-31 12:34:15 | GlaxoSmithKline Reported Revenue Growth in 2Q17

2017-08-30 16:36:05 | Inside Novartis’s 2Q17 Revenues

2017-08-29 13:12:58 | Bristol-Myers Squibb’s Valuation after 2Q17 Earnings

2017-08-23 12:42:45 | Dividend Yield of Franklin Resources